Empagliflozin
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Empagliflozin: Focal stiff limb syndrome
One-Sentence Summary
Empagliflozin is a drug used for type 2 diabetes mellitus (this use is recorded in the knowledge graph; the licence records compiled for this report contain no indication text). The TxGNN model predicts it may be relevant to focal stiff limb syndrome, but there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Focal stiff limb syndrome |
| TxGNN Prediction Score | 0.9906 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (20 of 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | 20 (valid: 20) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Empagliflozin is known as an SGLT2 inhibitor that acts on glucose reabsorption in the kidney’s proximal tubule.
Focal stiff limb syndrome is a rare neurological disorder within the stiff person spectrum, involving impaired GABA-mediated inhibition and often anti-GAD65 autoimmunity. No established mechanistic link to empagliflozin was identified. Any connection would be speculative, such as indirect anti-inflammatory or metabolic effects, or the shared association of anti-GAD autoimmunity with diabetes.
The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases (diabetes and autoimmunity associations), not biological evidence or a pharmacological rationale.
Two other predictions had identical or near-identical scores and were likewise unsupported: classic stiff person syndrome (0.9906) and opsismodysplasia (0.9903). For stiff person syndrome, the link is comorbidity with diabetes and autoimmunity. For opsismodysplasia, the link is a skeletal dysplasia caused by INPPL1 (SHIP2) mutations that touches insulin signalling. Neither is supported by a pharmacological mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Empagliflozin is marketed in India. The records contain no approved-indication text. Five main licences are listed below.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 113870 | Jardiance 10mg Tablet | Strip of 10 tablets | Boehringer Ingelheim |
| 113866 | Jardiance 25mg Tablet | Strip of 10 tablets | Boehringer Ingelheim |
| 72505 | Empaone 10mg Tablet | Strip of 10 tablets | MSN Laboratories |
| 94310 | Gibtulio 10mg Tablet | Strip of 10 tablets | Lupin Ltd |
| 162085 | Oboravo 10mg Tablet | Strip of 10 tablets | Cipla Ltd |
Safety Considerations
- Drug Interactions: 369 interactions are recorded. Most of those listed are of moderate severity, for example phenylephrine, acebutolol, acetazolamide, formoterol, pseudoephedrine, nifedipine, epinephrine, ethinylestradiol, hydrocortisone, salbutamol, ethanol, furosemide and fosinopril. Hydrocortisone (topical) and alclometasone (topical) are minor.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trial or publication studies empagliflozin in focal stiff limb syndrome, and no mechanistic link is established. The high TxGNN score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence or pharmacology, so the evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data for empagliflozin
- Package insert warnings and contraindications, which are required before safety screening
- Preclinical or mechanistic studies showing a plausible link to GABAergic or autoimmune pathways in stiff person spectrum disorders
- Case reports or exploratory studies in patients with focal stiff limb syndrome
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.